Since the mid-1940’s, antibiotics have served the test of time in reducing both morbidity and mortality rates from pathogenic infections. Now, these little, but virulent, bacteria cells have caught on to the way antibiotics communicate with bacteria; and they create a constant “busy signal” that prevents the bacteria from listening to the antibiotics’ call for wellness and prevents them from penetrating and delivering its medicine to the appropriate location in the bacteria, resulting in inflammation, pain, and infection. This phenomena has resulted in a pandemic wherein current-day antibiotics no longer respond in the expected manner.From the world of bacteriology, we’ve recently learned that bacteria form quorums.
A quorum is a deliberative group of germs that work in unison to plan their pattern of attack, creating infections in or on our bodies. Physicians call this communication event quorum sensing (QS).
The Bioavivus Strategy
Instead of developing new antibiotics from scratch and to avoid extremely risky costs* of such a challenge, Bioavivus Pharma has re-focused its research from attempting to creating new antibiotics to a strategy of exploiting newly discovered communication pathways that obliterate these “busy bacteria signals”. In other words, we’ve discovered and patented the first drug to inhibit quorum sensing. This opens up a new ultra-fast “expressway” to transport our drug to its home target, resulting in recovery and healing from infectious diseases. Our initial destination is to inhibit one of the most pathogenic bacteria (Pseudomonas aeruginosa) from traveling on our expressway.
* the Tufts Center for the study of drug development released an estimate of $2.6 billion to bring a new antibiotic to market